THE DRUG DOCKETXbrane's ranibizumab-blrz cleared the FDA on 27 October as a biosimilar to Lucentis. The injection is approved for wet AMD, macular oedema after retinal vein occlusion, and myopic choroidal neovascularisation.
3 min read
A final question-and-answer guidance tells biosimilar makers what data to file when they change how an approved product is made, fulfilling a 2022 user-fee commitment. It was issued on 13 October 2026.
3 min read
WHAT THE STUDY ACTUALLY SAYSIn a 462-person phase 3 trial, a synthesised copy of semaglutide, HD1916, cut body weight 13.1% over 44 weeks against 14.4% for the branded drug — inside the margin set for calling them equivalent.
4 min read
A hybrid public meeting on 26 October will discuss proposed BsUFA IV recommendations. The fees that fund FDA review of biosimilar applications expire in September 2027 and need new legislation to continue.
3 min read
EXPLAINERThe FDA's approval bar requires no clinically meaningful difference from the original, and a large switching trial found no loss of control. The savings gap is a market problem, not a safety one.
4 min read
WHAT THE STUDY ACTUALLY SAYSIn the head-to-head OVERLORD-MS trial, 92.2% on rituximab and 94.8% on ocrelizumab had no new MRI lesions from months 6 to 24, meeting the prespecified bar for noninferiority.
4 min read
Seven of those nine were denosumab. The committee's September opinions also covered an RSV antibody for infants, a first EU treatment for IgG4-related disease, and four withdrawn applications.
4 min read